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I D  C A S E
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Tenofovir disoproxil fumarate (TDF) has been used world-
wide in antiretroviral regimens of human immunodeficiency 
virus (HIV)-infected patients since being approved by the 
US Food and Drug Administration in 2001. Tenofovir dis-
oproxil fumarate can cause renal tubular dysfunction and 
reduced renal function [1]. In its fully developed form, TDF 
renal dysfunction is associated with hypophosphatemia, renal 
phosphate wasting, and other features of Fanconi syndrome 
[1]. Cases of TDF-associated Fanconi syndrome have been 
reported predominantly among patients with HIV infection 
[1]. There has been no excess risk of renal tubular toxicity 
with TDF-emtricitabine (TDF-FTC) detected in large, place-
bo-controlled trials of HIV pre-exposure prophylaxis (PrEP) 
[2, 3]. One other well documented likely Fanconi syndrome 
has been reported in an online supplement to the latter paper 
[3]. In this study, we report an additional case of this previ-
ously described phenomenon.
CASE REPORT
A 49-year-old white man with an single episode of kidney 
stones 7 years earlier and no ongoing medical problems or med-
ication use initiated daily PrEP with TDF-FTC in California 
Collaborative Treatment Group (CCTG) study 595 (NCT 
01761643). He had no subjective complaints while on the drug. 
There was no history of renal parenchymal disease and no 
recent symptoms or findings of nephrolithiasis, but, as shown in 
the Table 1, mild renal impairment was present at baseline with 
an estimated creatinine clearance of 79.9 mL/minute. Baseline 
testing for hepatitis B virus (HBV) and hepatitis C virus was 
negative. Routine monitoring at week 12 of treatment showed 
25% fall in estimated creatinine clearance (Table 1). Additional 
testing at week 12 revealed hypophosphatemia with renal phos-
phate wasting, consistent with Fanconi syndrome. Tenofovir 
disoproxil fumarate-FTC was discontinued. Four weeks later, 
there was improvement in creatinine clearance with resolution 
of phosphate abnormalities. By week 24 (12 weeks off TDF-
FTC), creatinine clearance had risen to near baseline levels. He 
was not rechallenged and remained HIV negative throughout. 
Neither glycosuria, hematuria, nor proteinuria were detected 
by dipstick at any time point. No other similar cases were doc-
umented in CCTG 595 (N = 400) during 577 person-years of 
follow up.
DISCUSSION
This HIV-uninfected man presented an unambiguous renal 
tubular toxicity due to TDF that was rapidly reversible. In the 
Pre-exposure Prophylaxis Initiative (iPrex) study of PrEP, a care-
fully performed renal substudy of 1137 participants [2] showed 
no excess renal tubulopathy (including hypophosphatemia, 
proteinuria, glycosuria, and fractional excretion of urate or 
phosphorus) among TDF-FTC recipients compared with pla-
cebo for PrEP. There was a decrease in estimated creatinine 
clearance that averaged ~1–2 mL/minute over the 144 weeks of 
the study with TDF-FTC compared with placebo, which nor-
malized upon drug discontinuation [2]. Another randomized, 
placebo-controlled study of daily PrEP with TDF or TDF-FTC 
among HIV-uninfected African men and women examined 
proximal tubule dysfunction, defined as the occurrence of ≥2 of 
the following at the same time point: tubular proteinuria, eug-
lycemic glycosuria, increased urinary excretion of phosphorus, 
and increased urinary excretion of uric acid. The authors found 
over a median drug-exposure period of 24  months, tubular 
damage occurred in <2% of participants [3]. Similar to iPrex, 
rates of tubular dysfunction did not differ by treatment arm in 
that study. As in our study, the authors also suggest that moni-
toring for tubular dysfunction may be prudent for individuals at 
increased risk for renal injury. It is worth noting that our patient 
may have had pre-existing renal dysfunction with a calculated 
creatinine clearance of 80. This may have predisposed him to 
TDF-related renal dysfunction as a result.
One limitation of our report is the lack of baseline data 
on phosphorus/urinary phosphorus levels. Screening for 
hypophosphatemia is not routine when considering PrEP. 
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However, there was a clear development of significant renal 
impairment accompanied by a low serum phosphate that 
resolved upon drug discontinuation. In spite of concurrent 
hypophosphatemia, the fractional excretion of phosphate was 
elevated, confirming inappropriate renal tubular function at the 
time of drug discontinuation.
Renal dysfunction has been reported in other settings with 
TDF in patients without HIV infection, such as HBV [4, 5]. 
Overt instances of Fanconi syndrome have been rarely reported 
[4]. A 60-month retrospective study of renal toxicity compared 
the effect of TDF-FTC in patients’ dual infection with HIV 
and HBV with those with HBV monoinfection [5]. That study 
showed a statistically significant decrease of renal function dur-
ing long-term TDF use in both groups, averaging 9 mL/minute 
in the coinfected group and 23 mL/minute in the HBV monoin-
fected group (P < .01). It is notable that those with HBV alone 
had a greater proportion (69%) that developed a glomerular 
filtration rate <90 mL/minute than those with HIV/HBV coin-
fection (12%). However, the the authors believed that the clin-
ical impact was not clinically relevant and no cases of Fanconi 
syndrome occurred [5].
CONCLUSIONS
Although significant nephrotoxicity has been rarely reported, 
periodic renal monitoring is a reasonable recommendation 
in HIV-uninfected individuals receiving TDF-FTC for PrEP 
and other conditions. This case and others [3] document that, 
albeit uncommon, a reversible TDF-FTC-associated Fanconi 
syndrome may nonetheless occur during PrEP. It is possible 
that pre-existing renal impairment may have contributed in this 
instance.
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Table 1. Laboratory Testing
Test Screen Week 4 Week 12 Week 16 Week 18 Week 21 Week 24
Estimated creatinine clearancea, mL/min 79.9 68.7 58.9
Stop TDF-FTC
69.1 66.6 71.0 74.0
Serum creatinine, mg/dL 1.15 1.33 1.58 1.28 1.32 1.27 1.20
Serum phosphorus, mg/dL (normal 2.7–4.5) — — 1.8 2.7 3.2 2.6 2.8
Fractional excretion of Phosphate, % (nor-
mal 10–20)
— — 26.6 12.2 — — —
Abbreviations: FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.
aEstimated creatinine clearance by Cockcroft-Gault formula.
